Shionogi reports success in late stage trial for drug to treat constipation from painkiller medication

5 August 2015

Japanese pharmaceutical company Shionogi (TYO: 4507) on Wednesday said a late-stage trial of its drug candidate to treat constipation caused by painkiller medication has met its primary and secondary endpoint.

The company in a statement said this is the third Phase III trial for its once-daily naldemedine to treat opioid-induced constipation (OIC). Naldemedine is an investigational, oral, peripherally acting mu-opioid receptor antagonist (pamora).

Juan Camilo Arjona Ferreira, senior vice president clinical development, said: "OIC is different from other forms of constipation as it is the most common side effect of chronic opioid therapy. OIC can hamper everyday activities, reduce work productivity and negatively affect a person's well-being."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK